Xiang Kun, Tietz Elizabeth I
Department of Physiology and Pharmacology, University of Toledo College of Medicine, Health Science Campus, Toledo, Ohio 43614, USA.
Behav Pharmacol. 2007 Sep;18(5-6):447-60. doi: 10.1097/FBP.0b013e3282d28f2b.
Withdrawal from 1-week oral administration of the benzodiazepine, flurazepam (FZP) is associated with increased alpha-amino-3-hydroxy-5-methylisoxasole-4-propionic acid (AMPA) receptor (AMPAR) miniature excitatory postsynaptic currents (mEPSCs) but reduction of N-methyl-D-aspartic acid (NMDA) receptor (NMDAR)-evoked (e)EPSCs in hippocampal CA1 neurons. A positive correlation was observed between increased AMPAR-mediated mEPSC amplitude and anxiety-like behavior in 1-day FZP-withdrawn rats. These effects were disrupted by systemic AMPAR antagonist administration (GYKI-52466, 0.5 mg/kg, intraperitoneal) at withdrawal onset, strengthening the hypothesis that CA1 neuron AMPAR-mediated hyperexcitability is a central component of a functional anatomic circuit associated with the expression of withdrawal anxiety. Abolition of AMPAR current upregulation in 2-day FZP withdrawn rats by GYKI-52466 injection also reversed the reduction in NMDAR-mediated eEPSC amplitude in CA1 neurons from the same rats, suggesting that downregulation of NMDAR function may serve a protective, negative-feedback role to prevent AMPAR-mediated neuronal overexcitation. NMDAR antagonist administration (MK-801, 0.25 mg/kg intraperitoneally) had no effect on modifying increased glutamatergic strength or on withdrawal anxiety, whereas injection of an L-type voltage-gated calcium channel antagonist, nimodipine (10 mg/kg, intraperitoneally) averted AMPAR current enhancement and anxiety-like behavior, suggesting that these manifestations may be initiated by a voltage-gated calcium channel-dependent signal transduction pathway. An evidence-based model of likely cellular mechanisms in the hippocampus contributing to benzodiazepine withdrawal anxiety was proposed implicating regulation of multiple CA1 neuron ion channels.
连续1周口服苯二氮䓬类药物氟西泮(FZP)后停药,海马CA1神经元中α-氨基-3-羟基-5-甲基异恶唑-4-丙酸(AMPA)受体(AMPAR)介导的微小兴奋性突触后电流(mEPSCs)增加,但N-甲基-D-天冬氨酸(NMDA)受体(NMDAR)介导的兴奋性突触后电流(eEPSCs)减少。在停药1天的FZP大鼠中,观察到AMPAR介导的mEPSC幅度增加与焦虑样行为之间存在正相关。在停药开始时全身给予AMPAR拮抗剂(GYKI-52466,0.5 mg/kg,腹腔注射)可破坏这些效应,强化了以下假说:CA1神经元AMPAR介导的过度兴奋性是与停药焦虑表达相关的功能性解剖回路的核心组成部分。在停药2天的FZP大鼠中,通过注射GYKI-52466消除AMPAR电流上调,也逆转了同组大鼠CA1神经元中NMDAR介导的eEPSC幅度的降低,表明NMDAR功能下调可能起到保护的负反馈作用,以防止AMPAR介导的神经元过度兴奋。给予NMDAR拮抗剂(MK-801,0.25 mg/kg,腹腔注射)对改变谷氨酸能增强或停药焦虑没有影响,而注射L型电压门控钙通道拮抗剂尼莫地平(10 mg/kg,腹腔注射)可避免AMPAR电流增强和焦虑样行为,表明这些表现可能由电压门控钙通道依赖性信号转导通路引发。提出了一个基于证据的海马体中可能导致苯二氮䓬类药物停药焦虑的细胞机制模型,涉及多个CA1神经元离子通道的调节。